Vitality Biopharma has developed a cannabis-based potential treatment for inflammatory bowel diseases. Its annoucement about VITA-100 comes as U.S. regulators have been approving cannabis-based products for various disorders. VITA-100 delivers two of the active ingredients in cannabis plants to the intestinal tract to alleviate inflammation there. Those components are cannabidiol and tetrahydrocannabinol, or THC. Vitality calls the new class of treatments it is developing for gut disorders cannabinoid prodrugs. The body converts them into a form that helps them do a better job of targeting specific organs or tissue, the company said. The U.S. Food and Drug Administration has approved Abbvie's formulation of THC sold under the name Dronabinol to stimulate appetite and reduce nausea and vomiting. The medication acts on the central nervous system. Since VITA-100's action is limited to the gut, it does not cause psychotropic problems in the brain. Preclinical-trial studies in animal models of bowel disease have shown that cannabis-based therapies can reduce colon damage and prevent weight loss, Vitaly said. The result was a significant improvement in gastrointestinal health, compared with animals taking a placebo. Researchers also achieved good results when they used cannabis-based therapies to treat mice with a specific bowel disease — ulcerative colitis.